Endocrine Abstracts

Objective: To assess metabolic disorders and thyroid function in patients with prostate cancer, who were treated with gonadotropin-releasing hormone(GnRH) agonist. Study design follow-up study.Materials and methods: 102 patients were enrolled to the study, 99 subjects were followed up till the study completion. The mean age was 69 years old (95% confidence range: 61.5–79.2 years old). To assess thyroid function, thyroid-stimulating hormone (TSH) an...

Introduction: Androgen deprivation therapy (ADT) is widely used around the world for the treatment various stages of prostate cancer. Androgen deprivation therapy (ADT) in men with prostate cancer (PCa) increased chance of developing metabolic disorders in insulin sensitivity, lipid levels, glucose metabolism, body composition (increases fat accumulation concurrently with a decrease in lean mass). These changes are the risk factors for the development of adverse cardiovascular...